Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02193490 · ClinicalTrials.gov registry record · Phase 1
DNase Treatment for Dry Eyes
A Phase 1 study, sponsored by University of Illinois at Chicago.
- Terminated
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT02193490 is a Phase 1 study that was terminated before completion, run by University of Illinois at Chicago. The registered enrollment target is 47 participants.
The verdict
NCT02193490, a Phase 1 study, was terminated before completion, sponsored by University of Illinois at Chicago.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the tolerability and preliminary efficacy of DNase eye drops in patients with Sjogren's and Non-Sjogren Dry Eye Disease.
Interventions
- DRUG Vehicle
- DRUG DNase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2014-07 |
| Est. Completion | 2017-10-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02193490
The ClinicalTrials.gov registry entry for NCT02193490 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT02193490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02193490 about?
NCT02193490 is a clinical study titled "DNase Treatment for Dry Eyes". The purpose of this study is to evaluate the tolerability and preliminary efficacy of DNase eye drops in patients with Sjogren's and Non-Sjogren Dry Eye Disease.
What is the current status of trial NCT02193490?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2014-07. Estimated completion is 2017-10-11.
What interventions are being tested in trial NCT02193490?
The interventions under investigation include: Vehicle (DRUG), DNase (DRUG).
Who is sponsoring clinical trial NCT02193490?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.